Tong Xin, Li Tiezheng, Li Chao, Wang Lai-Xi
Department of Chemistry and Biochemistry , University of Maryland , College Park , Maryland 20742 , United States.
Biochemistry. 2018 Sep 4;57(35):5239-5246. doi: 10.1021/acs.biochem.8b00719. Epub 2018 Aug 22.
Chemoenzymatic glycan remodeling by endoglycosidase-catalyzed deglycosylation and reglycosylation is emerging as an attractive approach for producing homogeneous glycoforms of antibodies, and the success of this approach depends on the discovery of efficient endoglycosidases and their glycosynthase mutants. We report in this paper a systematic site-directed mutagenesis of an endoglycosidase from Streptococcus pyogenes (Endo-S) at the critical Asp-233 (D233) site and evaluation of the hydrolysis and transglycosylation activities of the resulting mutants. We found that in addition to the previously identified D233A and D233Q mutants of Endo-S, most of the Asp-233 mutants discovered here were also glycosynthases that demonstrated glycosylation activity using glycan oxazoline as the donor substrate with diminished hydrolytic activity. The glycosynthase activity of the resultant mutants varied significantly depending on the nature of the amino acid substituents. Among them, the D233M mutant was identified as the most efficient glycosynthase variant with the highest transglycosylation/hydrolysis ratio, which is similar to the recently reported D184M mutant of Endo-S2, another S. pyogenes endoglycosidase. Kinetic studies of the D233M and D233A mutants of Endo-S, as well as glycosynthase mutants D184M and D184A of Endo-S2, indicated that the enhanced catalytic efficacy of the Asp-to-Met mutants of both enzymes was mainly due to an increased turnover number (increased k) for the glycan oxazoline substrate and the significantly enhanced substrate affinity (as judged by the reduced K value) for the antibody acceptor.
通过内切糖苷酶催化的去糖基化和再糖基化进行化学酶促聚糖重塑,正成为一种生产抗体均一糖型的有吸引力的方法,而这种方法的成功取决于高效内切糖苷酶及其糖基合酶突变体的发现。我们在本文中报道了对化脓性链球菌内切糖苷酶(Endo-S)关键的天冬氨酸-233(D233)位点进行系统的定点诱变,并对所得突变体的水解和转糖基化活性进行评估。我们发现,除了之前鉴定的Endo-S的D233A和D233Q突变体之外,这里发现的大多数天冬氨酸-233突变体也是糖基合酶,它们以聚糖恶唑啉作为供体底物表现出糖基化活性,同时水解活性降低。所得突变体的糖基合酶活性根据氨基酸取代基的性质有显著差异。其中,D233M突变体被鉴定为最有效的糖基合酶变体,具有最高的转糖基化/水解比,这与最近报道的另一种化脓性链球菌内切糖苷酶Endo-S2的D184M突变体相似。对Endo-S的D233M和D233A突变体以及Endo-S2的糖基合酶突变体D184M和D184A的动力学研究表明,这两种酶的天冬氨酸到甲硫氨酸突变体催化效率的提高主要是由于聚糖恶唑啉底物的周转数增加(k增加)以及对抗体受体的底物亲和力显著增强(通过降低的K值判断)。